BR9710893A - Uso de tiagabina ou de um sal farmaceuticamente aceit vel da mesma e processos de tratamento de distÚrbios psicÄticos e de distÚrbios de mania em seres humanos ou em animais - Google Patents

Uso de tiagabina ou de um sal farmaceuticamente aceit vel da mesma e processos de tratamento de distÚrbios psicÄticos e de distÚrbios de mania em seres humanos ou em animais

Info

Publication number
BR9710893A
BR9710893A BR9710893A BR9710893A BR9710893A BR 9710893 A BR9710893 A BR 9710893A BR 9710893 A BR9710893 A BR 9710893A BR 9710893 A BR9710893 A BR 9710893A BR 9710893 A BR9710893 A BR 9710893A
Authority
BR
Brazil
Prior art keywords
disorders
tiagabine
humans
animals
processes
Prior art date
Application number
BR9710893A
Other languages
English (en)
Inventor
Anders Fink-Jensen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of BR9710893A publication Critical patent/BR9710893A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
BR9710893A 1996-07-31 1997-07-25 Uso de tiagabina ou de um sal farmaceuticamente aceit vel da mesma e processos de tratamento de distÚrbios psicÄticos e de distÚrbios de mania em seres humanos ou em animais BR9710893A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK82496 1996-07-31
PCT/DK1997/000320 WO1998005330A1 (en) 1996-07-31 1997-07-25 Treatment of psychotic disorders

Publications (1)

Publication Number Publication Date
BR9710893A true BR9710893A (pt) 1999-08-17

Family

ID=8097971

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9710893A BR9710893A (pt) 1996-07-31 1997-07-25 Uso de tiagabina ou de um sal farmaceuticamente aceit vel da mesma e processos de tratamento de distÚrbios psicÄticos e de distÚrbios de mania em seres humanos ou em animais

Country Status (18)

Country Link
US (1) US5914333A (pt)
EP (1) EP0920316B1 (pt)
JP (1) JP2000515156A (pt)
KR (1) KR20000029525A (pt)
CN (1) CN1226828A (pt)
AT (1) ATE330604T1 (pt)
AU (1) AU728191B2 (pt)
BR (1) BR9710893A (pt)
CA (1) CA2260863C (pt)
CZ (1) CZ29899A3 (pt)
DE (1) DE69736180T2 (pt)
ES (1) ES2268732T3 (pt)
HU (1) HUP9904030A3 (pt)
IL (1) IL128028A0 (pt)
NO (1) NO990450L (pt)
PL (1) PL331321A1 (pt)
WO (1) WO1998005330A1 (pt)
ZA (1) ZA976854B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5914333A (en) * 1996-07-31 1999-06-22 Novo Nordisk A/S Treatment of psychotic disorders
IE970588A1 (en) 1997-08-01 2000-08-23 Elan Corp Plc Controlled release pharmaceutical compositions containing tiagabine
DK0991409T3 (da) * 1997-08-01 2002-03-25 Elan Corp Plc Farmaceutiske tiagabinindeholdende præparater med reguleret frigivelse
FR2771292B1 (fr) * 1997-11-21 2000-02-18 Ethypharm Lab Prod Ethiques Spheroides contenant de la tiagabine, procede de preparation et compositions pharmaceutiques
ES2246485T3 (es) * 1999-07-01 2006-02-16 PHARMACIA & UPJOHN COMPANY LLC (s,s)-reboxetina para tratar la incontinencia.
US6270438B1 (en) * 1999-12-22 2001-08-07 Yuan-Cheng Liao Combination driving hub for bicycle
WO2005000294A1 (en) * 2003-06-06 2005-01-06 Pharmacia Corporation Selective inhibitor and an anticonvulsant agent for the treatment of central nervous system disorders
US20090139311A1 (en) 2007-10-05 2009-06-04 Applied Biosystems Inc. Biological Analysis Systems, Devices, and Methods

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4383999A (en) * 1981-05-26 1983-05-17 Smithkline Beckman Corporation Inhibition of GABA uptake by N-substituted azaheterocyclic carboxylic acids and their esters
DK288385D0 (da) * 1985-06-26 1985-06-26 Novo Industri As Aminosyrederivater
DK58291D0 (da) * 1991-04-02 1991-04-02 Novo Nordisk As Krystalinsk stof og dets fremstilling
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
US5750140A (en) * 1994-05-20 1998-05-12 Novo Nordisk A/S Transdermal delivery of tiagabine
US5767117A (en) * 1994-11-18 1998-06-16 The General Hospital Corporation Method for treating vascular headaches
AU707508B2 (en) * 1995-05-05 1999-07-15 Novo Nordisk A/S Pharmaceutical composition containing tiagabine hydrochloride and the process for its preparation
DE19525598C2 (de) * 1995-07-13 1997-09-25 Max Planck Gesellschaft Schlafmittel
UA52661C2 (uk) * 1996-06-14 2003-01-15 Ново Нордіск А/С Безводна кристалічна форма гідрохлориду r(-)-n-(4,4-ди(3-метилтієн-2-іл)бут-3-еніл) ніпекотинової кислоти
US5914333A (en) * 1996-07-31 1999-06-22 Novo Nordisk A/S Treatment of psychotic disorders
DK174041B1 (da) * 1998-11-26 2002-05-06 Monarflex As Gennemføring til montering i en fleksibel membran

Also Published As

Publication number Publication date
DE69736180D1 (de) 2006-08-03
HUP9904030A3 (en) 2000-07-28
CA2260863A1 (en) 1998-02-12
EP0920316A1 (en) 1999-06-09
ES2268732T3 (es) 2007-03-16
KR20000029525A (ko) 2000-05-25
ATE330604T1 (de) 2006-07-15
IL128028A0 (en) 1999-11-30
US5914333A (en) 1999-06-22
CN1226828A (zh) 1999-08-25
NO990450D0 (no) 1999-01-29
AU3619797A (en) 1998-02-25
CA2260863C (en) 2008-02-12
WO1998005330A1 (en) 1998-02-12
DE69736180T2 (de) 2007-06-14
CZ29899A3 (cs) 1999-06-16
ZA976854B (en) 1998-03-19
HUP9904030A2 (hu) 2000-05-28
AU728191B2 (en) 2001-01-04
PL331321A1 (en) 1999-07-05
NO990450L (no) 1999-01-29
JP2000515156A (ja) 2000-11-14
EP0920316B1 (en) 2006-06-21

Similar Documents

Publication Publication Date Title
DE60131775D1 (de) Eine implantierbare oder einführbare vorrichtung zur abgabe therapeutischer mittel
ATE241334T1 (de) Mittel zur förderung des haarwachstums
DE69737367D1 (de) Einrichtung zur steuerung eines glatten muskels
DE69630947D1 (de) Mittel zur schmerzbehandlung
BR9508751A (pt) Composto formulação e processos de tratamento ou profilaxia de disfunções psicóticas ou disfunções de debilitação intelectual e da ansiedade e de preparação do composto
DE59607691D1 (de) Anordnung zur elektro-thermischen behandlung des menschlichen oder tierischen körpers
DE69524138T2 (de) Hautbehandlungsmittel
KR970704445A (ko) 페노티아진 및/또는 티옥산틴을 사용한 알츠하이머 병의 치료 및/또는 예방 방법(methods for treating and/or preventing alzheimer's disease using phenothiazines and/or thioxanthenes
PT969845E (pt) Novas combinacoes terapeuticas de mirtazapina e agentes antipsicoticos, para tratamento ou profilaxia de desordens psicoticas
ATE229338T1 (de) 2',2'-difluornucleoside zur immunosuppressiven therapie und kombinationspräparate
BR9710893A (pt) Uso de tiagabina ou de um sal farmaceuticamente aceit vel da mesma e processos de tratamento de distÚrbios psicÄticos e de distÚrbios de mania em seres humanos ou em animais
DE69729004D1 (de) Photodynamische therapie zur behandlung von osteosrthritis
IT1290781B1 (it) Agente attivo terapeutico per il trattamento di malattie degenerative neuronali.
DK1726651T3 (da) Fremgangsmåde til behandling af muskulære lidelser
ID23528A (id) Pengobatan terapeutik untuk gangguan kulit
MX9707642A (es) Uso de 2-oxoindol-1-carboxamidas 3-sustituidas y sus sales de base farmaceuticamente aceptables para preparar composiciones para el tratamiento y prevencion de la enfermedad de alzheimer en mamiferos, incluyendo a humanos.
PT932400E (pt) Derivados de anticonvulsionantes uteis no tratamento da dor neuropatica
ZA972601B (en) Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of cancer
EP0921803A4 (en) METHOD FOR PREVENTING AND TREATING PESTVIRUS INFECTIONS AND RELATED DISEASES
BR0113646A (pt) Tratamento de distúrbios inflamatórios
PT983300E (pt) Sais peptidicos de bpc com actividade organo-protectora, processo para a sua preparacao e sua utilizacao em terapia
BR9506838A (pt) Derivados de ácido micofenólico substituídos na posição 5
BA98363A (bs) Postupak i uredaj za tretiranje koze i tome slicno
BR9708037A (pt) Método para o tratamento de abuso de substância
DE29707744U1 (de) 4-Phenylbutyrat enthaltende Mittel zur antineoplastischen Therapie

Legal Events

Date Code Title Description
EG Technical examination (opinion): publication of technical examination (opinion)
FB36 Technical and formal requirements: requirement - article 36 of industrial property law
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIMENTO DO PRESENTE PEDIDO, COM BASE NOS ARTIGOS 8O E 13 DA LEI NO 9279/96

B12B Appeal against refusal [chapter 12.2 patent gazette]